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Abstract 
Objectives:  To create easy to understand, antidepressant medication decision making aids and describe the process used to develop 
the aids for patients diagnosed with depression.  Methods:  In collaboration with the Institute for Clinical Systems Improvement 
(ICSI), antidepressant medication decision making aids were developed to enhance patient and physician communication about 
medication selection.  The final versions of the aids were based on design methods created by Dr. Victor M. Montori (Mayo Clinic) 
and discussions with patients and providers.  Five physicians used prototype aids in their outpatient clinics to assess their usefulness.   
Results:  Six prototype antidepressant medication decision making aids were created to review potential side-effects of 
antidepressant medications.  The side effects included were those patients feel are most bothersome or may contribute to premature 
discontinuation of antidepressant treatment, including: weight changes, sexual dysfunction, sedation, and other unique side effects.  
The decision aids underwent several revisions before they were distributed to physicians.  Physicians reported patients enjoyed using 
the decision aids and found them useful.  The sexual dysfunction card was considered the most useful while the daily administration 
schedule card was felt to be the least useful.  Conclusions:  Physicians found the antidepressant decision making aids helpful and felt 
they improved their usual interactions with patients.  The aids may lead to more patient-centered treatment choices and empower 
patients to become more directly involved in their treatment.  Whether the aids improve patient’s medication adherence needs to be 
addressed in future studies.  
 
 
Introduction 
Approximately 14.8 million adults, or 6.7% of the United 
States (U.S.) population, suffer from depression annually.
1,2
  
Depression is often a chronic or recurrent disorder and may 
require patients to adhere to life-long treatment.
3,4
  The 
symptoms of depression are treatable, but depression is only 
detected in one-third to one-half of patients suffering from 
the illness.
5
  About one half of patients with depression are 
treated in the primary care setting and only 20-40% show 
significant improvement after one year.
1,6,7
  
 
The American Psychiatric Association’s (APA), Practice 
Guideline for the Treatment of Patients with Major 
Depressive Disorder (Third Edition),
4
 outlines three phases for 
the treatment of depression: acute, continuation, and 
maintenance phases.  The goal of the acute phase is to 
achieve complete remission of the patient’s depressive 
symptoms.  The acute phase lasts a minimum of six to twelve 
weeks.  The goal of the continuation phase is to preserve 
remission and prevent symptom relapse.  The same 
antidepressant medication and dose should be used during 
both the acute and continuation treatment phases.  The 
maintenance phase should be considered for patients at risk 
of recurrence of depressive episodes. 
Effective treatment of depression requires patients actively 
participate in, and adhere to, treatment plans, despite side 
effects or burdensome treatment requirements.
4,8,9
  Patients 
may have strong preferences for medications based on 
previous experiences of family and friends.
4
  Considering 
these preferences during treatment decision making may 
improve adherence to treatment.
4,8,9
  Successful treatment of 
depression should also include the patient and their family 
actively participating in their care and ongoing education.
4
   
 
Antidepressant medications exhibit similar antidepressant 
efficacy between and within classes.  The initial selection of 
an antidepressant medication should be based on anticipated 
side effects.  The tolerability and safety of antidepressant side 
effects should be assessed for each individual patient.  
Selective Serotonin Reuptake Inhibitors (SSRIs), venlafaxine, 
duloxetine, mirtazapine, and bupropion are all first-line 
options for the treatment of depression.  These agents have 
more tolerable side effects than tricyclic antidepressants 
(TCAs) or mono-amine oxidase inhibitors (MAOIs).
4,8,9
 
 
Side effects complicate treatment because they often occur 
before benefit from the medication is recognized.
4
  Patients 
need to take an antidepressant for at least 6 to 12 months 
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after symptom remission to reduce the risk of symptom 
recurrence.
4,8
  Discontinuing the medication too early is 
associated with a 77% increase in recurrence of symptoms.
10
  
Untreated symptoms of depression, such as feelings of 
pessimism, low motivation, low energy, isolation, and guilt 
may also lead to patients stopping treatment prematurely.
4 
 
Patient’s attitudes may also impact compliance.  A study 
evaluating the reasons why patients stop their 
antidepressants found 55 percent stopped treatment when 
they started to feel better, 23 percent due to side effects, 10 
percent due to fear of becoming dependent on 
antidepressant medication, and 10 percent because of lack of 
efficacy.  Many patients believe their depression will resolve 
without intervention.  Patients may also adjust the dose of 
their antidepressant without discussing these changes with 
their prescriber.
11
   
 
Current guidelines for the treatment of depression strongly 
suggest incorporating patient specific preferences when 
selecting an antidepressant medication.
4,8,9
  Unfortunately, 
patients’ personal experience or preferences are not explicitly 
incorporated into the decision-making process of these 
guidelines.  Education on the potential side effects of 
antidepressant medications may help patients make 
informed decisions and adhere to treatment.  Research 
suggests the physician-patient relationship is critical in 
influencing medication adherence.  Patients who believe their 
physicians understand how they feel are more likely to tell 
them if they have been non-compliant.
11
  
 
Dr. Victor M. Montori (Mayo Clinic) has developed diabetes 
medication decision aids for antihyperglycemic medications.  
Implementation of the decision aids encouraged patients to 
ask their physicians questions and voice concerns.
12
  Dr. 
Montori and his team have also created decision aids to assist 
patients with type 2 diabetes select an appropriate statin to 
treat hypercholesterolemia.  This set of aids increased the 
proportion of patients who adhered to statins at three 
months and assisted in improved dialogue between patients 
and their providers.
13
  Decision making aids for osteoporosis 
in the primary care setting are currently being evaluated.
14 
 
The goal of the current study was to create similarly designed 
decision making aids for depression. These aids would assist 
patients and providers in the selection of a suitable 
antidepressant medication by initiating conversations about 
side effects, costs, and effective treatment of depression.  
The long-term goal is to evaluate the effectiveness of the aids 
and the process of shared decision making on overall patient 
compliance with antidepressant medication and treatment 
outcomes. 
Methods 
Antidepressant medication decision making aids were 
developed in collaboration with the Institute for Clinical 
Systems Improvement (ICSI).  Dr. Montori previously 
reviewed the process for developing diabetes decision 
making aids.
12
  The overall design of the antidepressant aids 
built on the fourth, and final prototype used in his study.   
 
The development of the antidepressant medication decision-
making aids started with selecting potential topics.  We 
consulted psychiatrists, primary care physicians, and 
members of ICSI to identify key areas patients and providers 
felt were important when selecting an antidepressant 
medication.   We also used accumulated, direct patient 
experience to further refine our themes and the overall 
content for the initial topics.  We reviewed commonly asked 
questions during patient-focused medication groups on 
inpatient units and during patient interviews as part of 
physician-requested pharmacy consults.  We initially came up 
with twelve potential topics. 
 
The primary resources for card content were Micromedex 
and standard, psychopharmacology reference books.  The 
symbols and layouts of the cards changed several times 
before they were distributed to physicians to help make them 
more patient-friendly (Fig. 1).  The final version of the aids 
was provided to five primary care physicians or psychiatrists 
in the Minneapolis/St. Paul Metropolitan area.   
 
This study did not require University of Minnesota, 
Institutional Review Board (IRB) approval because it was not 
considered human subjects research.  
 
Results 
The number of card topics was reduced from twelve to six 
based on physician feedback and to ensure patients would 
have time to evaluate the aids during a typical appointment.  
Decision aids were designed to address cost, daily 
administration schedule, and potential side effects like 
weight gain and sexual dysfunction  (Fig. 2).  The aids took the 
form of 9 inch x 3.5 inch paper, laminated cards.  Each card 
addressed one issue, such as sexual dysfunction, and then 
represented how it is affected by each of the first-line 
antidepressants.  Symbols and pictures on the cards help 
minimize text and made the cards more useful for people 
who have difficulty reading.  
 
The medications selected to be included in the 
antidepressant medication decision-making aids included all 
commercially available SSRIs and mixed-reuptake inhibitors 
(e.g., venlafaxine, bupropion, mirtazapine, and duloxetine) 
indicated for the treatment of major depression.  These 
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medications comprise approximately 98 percent of 
prescriptions commonly used during the initial treatment of a 
major depressive episode in our practices.  Monoamine 
oxidase inhibitors (MAOIs) are rarely seen until a patient has 
failed numerous other antidepressant treatment options.  
Tricyclic antidepressants (TCAs) are primarily used for 
neuropathic pain or for the treatment of insomnia, rather 
than depression.  We excluded both the MAOIs and TCAs for 
simplicity, their rare use as a first or second-line 
antidepressant treatment options, and because we already 
had multiple agents included in the aids. 
  
Physicians reported patients found the decision aids 
interesting and enjoyed using them.  The aids facilitated 
conversations and changed the normal interaction between 
the provider and patient.  The sexual dysfunction card was 
considered the most useful while the administration schedule 
card was least useful.  While the sexual dysfunction card was 
most useful, it was also the most confusing for patients 
because of the positive and negative symbols indicating the 
potential risk of each agent causing sexual side effects.  
Physicians suggested cards addressing dosing range, 
pregnancy category, breast feeding compatibility, mechanism 
of action, drug-drug interactions, and co-morbidities treated 
by each drug would also be useful for patients in the future. 
 
Discussion 
Six aids were designed to allow physicians enough time to 
discuss all topics with the patient.  Paper, rather than 
electronic, cards were developed so patients and physicians 
could easily use them in an exam room and to minimize 
technical difficulties.  Many patients used the cards but few 
were willing to provide direct feedback regarding their 
experience with the decision aids.  The decision aids likely 
influenced the content of the conversations and the 
questions asked by patients.   
 
Physicians are clinical experts and can provide a wealth of 
knowledge and clinical practice experience to a patient 
consultation.  However, physicians occasionally develop a 
short-list of first-choice antidepressant medications which 
may not be appropriate for all patients.  Patients are experts 
on how they feel and may be better able to define their 
overall level of depression and the degree to which it 
interferes with their day-to-day activities.  By providing 
details about their daily lifestyle (i.e., what time they wake 
up, when they eat meals, when they return from work, and 
the type of work they do), patients are providing important 
information necessary for the success of their antidepressant 
treatment.
12 
 
The aids were not meant to replace education provided by 
the physician but should encourage patients to ask questions 
and voice concerns.  The usefulness of the aids relies on the 
physician’s communication skills and clinical knowledge.  
These attributes are variable among physicians and could 
affect the overall experience the patient has with the decision 
aids.  Physicians in this study were provided with a user guide 
but were ultimately allowed to use the decision aids however 
they deemed appropriate. 
 
The design of the “administration schedule” card changed 
prior to distributing it to physicians to help minimize 
confusion (Fig. 1).  Team members from ICSI felt the sun and 
moon symbols would be easier for patients to understand, 
rather than the multiple capsules used on the first design.  
The cards contain all the necessary information but some of 
the symbols, such as the pluses and minuses on the sexual 
dysfunction card, were confusing to some patients.  Dr. 
Montori’s study incorporated a design team to assist with 
card layout and design. Future studies of the depression aids 
would benefit from the assistance of a graphics artist or 
design consultant. 
 
The topics of the six prototype cards were found to be 
relevant by patients and physicians.  However, there are 
other important issues that were not addressed by the cards, 
such as medication dose ranges or pregnancy safety category.  
Topics like pregnancy category would be useful for a smaller 
subset of patients, but would be extremely helpful when 
discussing the risks and benefits of treating depression during 
pregnancy. 
 
Physicians reported some patients were hesitant to use the 
decision making aids because they did not want to be part of 
a study.  Therefore, we had to rely on the physician’s 
interpretation of the patient interaction and could not 
analyze information directly provided by patients.  In the 
future, some type of incentive may need to be offered to 
patients to motivate them to provide feedback in the form of 
surveys or short-answer questions.  Dr. Montori offered 
patients 15 dollars for participating in his study with the 
osteoporosis decision aids but we did not have such funds 
available.
14
   
 
There are several potential barriers to the shared decision 
making process for mental health patients.  Patient insight 
regarding the need for treatment and their symptom severity, 
fears about social stigma if professional help is sought, 
attitudes about treatment, changes in symptom severity, and 
confusion about the many different treatment options can 
impact the shared decision making process.  While many 
patients with depression report they would like to receive 
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more time consulting with their physician and more 
information about their illness and treatment options, other 
patients prefer the physician to take action and make 
decisions.  The latter is generally true for patients who are 
too ill to take part in the process or make decisions about 
difficult situations.
15 
 
Barriers exist for physicians as well.  Shared decision making 
is a time consuming practice and physicians must be able to 
integrate patient preference, clinical judgment, and 
expanding scientific knowledge.
16,17
  Despite these barriers, 
simple and easy-to-understand decision making aids could 
greatly enhance mental health patients’ understanding of 
depression and the treatments available. 
 
While it appears the decision aids were easy to understand 
and changed the normal interaction between the provider 
and patient, more data is necessary to reach a conclusion.  
Dr. Montori has already shown that decision making aids for 
patients with diabetes are helpful for selecting diabetes 
medications and/or statins.  They help create conversations 
and patients ask more questions.  The decision making aids 
for statins increased adherence rates at three months but the 
aids for diabetes medications did not improve adherence.
13,18
  
The current study allowed for the successful design of six 
antidepressant decision aids and helped determine which of 
the aids need more work.  The development of additional 
cards can also begin based on feedback from physicians and 
patients.  Another study assessing the design of the cards and 
their usefulness is necessary before adherence and shared 
decision making can be addressed. In the future, an electronic 
version of the cards could also be developed.   
 
Dr. Montori and his team went through the design process 
for their diabetes decision aids and determined which design 
best facilitated a conversation between the clinician and 
patient about diabetes medication options.  The prototypes 
were evaluated in two ways.  They were used in actual clinical 
encounters and researchers recorded observations and later 
looked for patterns.  The second method involved a patient 
advisory group, in which participants role-played using the 
prototypes and then reflected on their experience.  
Researchers again looked for patterns and compared their 
reflections with the behaviors in the clinical encounters.  They 
used pattern recognition to identify problems and challenges 
and used these as opportunities to experiment with the 
prototypes.
12
  We relied on feedback from ICSI team 
members, physicians, and patients but did not have access to 
advisory or research teams.   
 
Dr. Montori’s first prototype provided bullet-form, 
quantitative information about the pros and cons of each 
medication (Fig. 3).  Each card described one medication or 
drug class and focused on numerical information.  This 
prototype did not prompt patients to ask questions or talk 
about the cards.  Patients found the information interesting 
but wanted the aids to provide a direct comparison across 
treatment options.  The second prototype was a narrative 
explanatory form and allowed patients to compare across 
medications (Fig. 4).  Patients understood the information on 
the cards but it did not change the interaction with the 
provider much.  The cards included too much text and 
patients still found it difficult to compare medication options.  
The third prototype listed medication options along the top 
of the card and categories along the left.  Velcro was affixed 
to the back of the cards and the patients and clinicians could 
arrange them on a decision board.  These cards generated 
more conversation but were cumbersome and still contained 
too much text.
12
  Our cards also underwent several revisions 
but we did not have access to a design team and did not have 
the funding to pay for a graphic artist.  
 
The final version of Dr. Montori’s aids focused on using 
pictures and symbols rather than words.  Instead of each 
medication having its own card, the cards described how 
each medication could affect the issue of interest (Fig. 5).  
This design generated conversation and changed the type of 
questions patients asked.
12
  Based on this success, the design 
for the antidepressant aids built on the final prototype used 
in his study.  There are some key differences, however.   
 
The medication classes on Dr. Montori’s aids are always listed 
in the same order (i.e. metformin, followed by insulin, 
followed by glitazones, etc.) to help patients easily compare 
the medications.  We were not able to replicate this with the 
antidepressant aids because there were more medications to 
compare and they did not fit nicely onto one card.  This may 
have made it more difficult for patients to locate a specific 
medication on each card and compare across treatment 
options.  Another difference is the choice of topics addressed 
by the aids.  For example, Dr. Montori did not address the 
cost associated with each agent because of the variety of 
medication benefits available.
12
  Another limitation to 
including cost data on a decision aid is the information 
outdates quickly and needs to be updated frequently.  
Despite these issues, we chose to address cost because we 
found it was a large concern for patients in our medication 
groups.  Many of our patients do not have insurance and 
cannot afford the more expensive, brand name products.   
 
In the future, we plan to assess the feasibility of the decision 
making aids through use of surveys that will be provided to 
physicians and patients.  We would also like to include 
pharmacists who are following mental health patients in 
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ambulatory care clinics and helping make treatment 
decisions.  This may be accomplished through collaboration 
with the College of Psychiatric and Neurologic Pharmacists 
(CPNP), which would allow us to disseminate the decision 
aids to other mental health pharmacists who could help 
assess and evaluate them in their practice settings. The 
surveys will be used to further evaluate the graphics on the 
aids, their readability, and ease of use.  Based on the results 
of this development study, we plan to create two more 
versions of the sexual dysfunction card so providers and 
patients can help determine which card is easiest to 
understand and has the most useful graphics.  Along with 
providing the user-manual we created for physicians, we plan 
to host in-services at participating sites to teach providers 
how to appropriately use the decision aids in practice.  We 
may also create an on-line link to the decision aids to assess 
the feasibility of using an electronic form versus hard copies 
in the provider’s office.  The final goal will be to evaluate the 
effectiveness of the aids and the process of shared decision 
making on overall patient compliance with antidepressant 
medication and treatment outcomes. 
   
Conclusion 
Antidepressant decision making aids appear to be useful for 
helping patients choose an initial antidepressant and 
increased discussion between the physician and patient.  The 
design of the cards plays an important role in how the patient 
interacts with the physicians and the type of questions asked.  
More studies are necessary to determine if the aids can shift 
the clinical visit from a disease-centered approach to a 
patient-centered approach.  Involving patients more in the 
decision making process may ultimately improve compliance 
and invest them more in their own health.  
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Figure 1: The aid on the right depicts the original version of the “Schedule”  
 card and the aid on the left represents the final prototype used in the study. 
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Figure 2: The six prototype cards used in the study. 
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Figure 3: An example of Dr. Montori’s first prototype. Reprinted with permission from reference 12. 
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Figure 4: An example of Dr. Montori’s second prototype. Reprinted with permission from reference 12. 
 
 
 
 
 
 
  
Resident Project PRACTICE-BASED RESEARCH 
 
http://z.umn.edu/INNOVATIONS                         2012, Vol. 3, No. 2, Article 80                         INNOVATIONS in pharmacy   10 
 
Figure 5: Dr. Montori’s final prototype set. Reprinted with permission from reference 12. 
 
 
 
